DOCSLIB.ORG

TR-583: Bromodichloroacetic Acid (CASRN 71133-14-7) in F344/N

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TR-583: Bromodichloroacetic Acid (CASRN 71133-14-7) in F344/N NTP TECHNICAL REPORT ON THE TOXICOLOGY STUDIES OF BROMODICHLOROACETIC ACID (CASRN 71133-14-7) IN F344/N RATS AND B6C3F1/N MICE AND TOXICOLOGY AND CARCINOGENESIS STUDIES OF BROMODICHLOROACETIC ACID IN F344/NTAC RATS AND B6C3F1/N MICE (DRINKING WATER STUDIES) NTP TR 583 OCTOBER 2015 NTP Technical Report on the Toxicology Studies of Bromodichloroacetic Acid (CASRN 71133-14-7) in F344/N Rats and B6C3F1/N Mice and Toxicology and Carcinogenesis Studies of Bromodichloroacetic Acid in F344/NTac Rats and B6C3F1/N Mice (Drinking Water Studies) Technical Report 583 October 2015 National Toxicology Program Public Health Service U.S. Department of Health and Human Services ISSN: 2378-8925 Research Triangle Park, North Carolina, USA Bromodichloroacetic Acid, NTP TR 583 Foreword The National Toxicology Program (NTP) is an interagency program within the Public Health Service (PHS) of the Department of Health and Human Services (HHS) and is headquartered at the National Institute of Environmental Health Sciences of the National Institutes of Health (NIEHS/NIH). Three agencies contribute resources to the program: NIEHS/NIH, the National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention (NIOSH/CDC), and the National Center for Toxicological Research of the Food and Drug Administration (NCTR/FDA). Established in 1978, NTP is charged with coordinating toxicological testing activities, strengthening the science base in toxicology, developing and validating improved testing methods, and providing information about potentially toxic substances to health regulatory and research agencies, scientific and medical communities, and the public. The Technical Report series began in 1976 with carcinogenesis studies conducted by the National Cancer Institute. In 1981, this bioassay program was transferred to NTP. The studies described in the Technical Report series are designed and conducted to characterize and evaluate the toxicologic potential, including carcinogenic activity, of selected substances in laboratory animals (usually two species, rats and mice). Substances selected for NTP toxicity and carcinogenicity studies are chosen primarily on the basis of human exposure, level of production, and chemical structure. The interpretive conclusions presented in NTP Technical Reports are based only on the results of these NTP studies. Extrapolation of these results to other species, including characterization of hazards and risks to humans, requires analyses beyond the intent of these reports. Selection per se is not an indicator of a substance’s carcinogenic potential. NTP conducts its studies in compliance with its laboratory health and safety guidelines and FDA Good Laboratory Practice Regulations and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use are in accordance with the Public Health Service Policy on Humane Care and Use of Animals. Studies are subjected to retrospective quality assurance audits before being presented for public review. The NTP Technical Reports are available free of charge on the NTP website and cataloged in PubMed, a free resource developed and maintained by the National Library of Medicine (part of the National Institutes of Health). Data for these studies are included in NTP’s Chemical Effects in Biological Systems database. For questions about the reports and studies, please email NTP or call 984-287-3211. ii Bromodichloroacetic Acid, NTP TR 583 Table of Contents Foreword ......................................................................................................................................... ii Tables ...............................................................................................................................................v Figures............................................................................................................................................ vi About This Report........................................................................................................................ viii Explanation of Levels of Evidence of Carcinogenic Activity ....................................................... xi Peer Review ................................................................................................................................. xiii Publication Details ....................................................................................................................... xiv Abstract ..........................................................................................................................................xv Two-week Study in F344/N Rats ..............................................................................................xv Two-week Study in Mice ..........................................................................................................xv Three-month Study in F344/N Rats ..........................................................................................xv Three-month Study in Mice ......................................................................................................xv Two-year Study in F344/NTac Rats ....................................................................................... xvi Two-year Study in Mice......................................................................................................... xvii Genetic Toxicology ............................................................................................................... xviii Conclusions ........................................................................................................................... xviii Overview of Water Disinfection By-products Program ............................................................. xxii Introduction ......................................................................................................................................1 Chemical and Physical Properties ...............................................................................................1 Formation, Occurrence, and Human Exposure ...........................................................................1 Absorption, Distribution, Metabolism, and Excretion ................................................................2 Experimental Animals .........................................................................................................2 Humans ................................................................................................................................3 Toxicity .......................................................................................................................................3 Experimental Animals .........................................................................................................4 Humans ................................................................................................................................5 Reproductive and Developmental Toxicity ................................................................................5 Experimental Animals .........................................................................................................5 Humans ................................................................................................................................8 Carcinogenicity ...........................................................................................................................9 Experimental Animals .........................................................................................................9 Humans ..............................................................................................................................11 Genetic Toxicity ........................................................................................................................11 Study Rationale .........................................................................................................................13 Materials and Methods ...................................................................................................................14 Procurement and Characterization of Bromodichloroacetic Acid ............................................14 Preparation and Analysis of Dose Formulations .......................................................................15 Animal Source ...........................................................................................................................15 Animal Welfare .........................................................................................................................16 Two-week Studies .....................................................................................................................16 iii Bromodichloroacetic Acid, NTP TR 583 Three-month Studies .................................................................................................................17 Two-year Studies ......................................................................................................................18 Study Design ......................................................................................................................18 Clinical Examinations and Pathology ................................................................................19 Molecular Pathology Studies .............................................................................................20 Statistical
Load more

Recommended publications
  • Transcriptomic and Proteomic Profiling Provides Insight Into
    BASIC RESEARCH www.jasn.org Transcriptomic and Proteomic Profiling Provides Insight into Mesangial Cell Function in IgA Nephropathy † † ‡ Peidi Liu,* Emelie Lassén,* Viji Nair, Celine C. Berthier, Miyuki Suguro, Carina Sihlbom,§ † | † Matthias Kretzler, Christer Betsholtz, ¶ Börje Haraldsson,* Wenjun Ju, Kerstin Ebefors,* and Jenny Nyström* *Department of Physiology, Institute of Neuroscience and Physiology, §Proteomics Core Facility at University of Gothenburg, University of Gothenburg, Gothenburg, Sweden; †Division of Nephrology, Department of Internal Medicine and Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan; ‡Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan; |Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; and ¶Integrated Cardio Metabolic Centre, Karolinska Institutet Novum, Huddinge, Sweden ABSTRACT IgA nephropathy (IgAN), the most common GN worldwide, is characterized by circulating galactose-deficient IgA (gd-IgA) that forms immune complexes. The immune complexes are deposited in the glomerular mesangium, leading to inflammation and loss of renal function, but the complete pathophysiology of the disease is not understood. Using an integrated global transcriptomic and proteomic profiling approach, we investigated the role of the mesangium in the onset and progression of IgAN. Global gene expression was investigated by microarray analysis of the glomerular compartment of renal biopsy specimens from patients with IgAN (n=19) and controls (n=22). Using curated glomerular cell type–specific genes from the published literature, we found differential expression of a much higher percentage of mesangial cell–positive standard genes than podocyte-positive standard genes in IgAN. Principal coordinate analysis of expression data revealed clear separation of patient and control samples on the basis of mesangial but not podocyte cell–positive standard genes.
    [Show full text]
  • Supplemental Information For
    Supplemental Information for: Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia Mary E. Ross, Rami Mahfouz, Mihaela Onciu, Hsi-Che Liu, Xiaodong Zhou, Guangchun Song, Sheila A. Shurtleff, Stanley Pounds, Cheng Cheng, Jing Ma, Raul C. Ribeiro, Jeffrey E. Rubnitz, Kevin Girtman, W. Kent Williams, Susana C. Raimondi, Der-Cherng Liang, Lee-Yung Shih, Ching-Hon Pui & James R. Downing Table of Contents Section I. Patient Datasets Table S1. Diagnostic AML characteristics Table S2. Cytogenetics Summary Table S3. Adult diagnostic AML characteristics Table S4. Additional T-ALL characteristics Section II. Methods Table S5. Summary of filtered probe sets Table S6. MLL-PTD primers Additional Statistical Methods Section III. Genetic Subtype Discriminating Genes Figure S1. Unsupervised Heirarchical clustering Figure S2. Heirarchical clustering with class discriminating genes Table S7. Top 100 probe sets selected by SAM for t(8;21)[AML1-ETO] Table S8. Top 100 probe sets selected by SAM for t(15;17) [PML-RARα] Table S9. Top 63 probe sets selected by SAM for inv(16) [CBFβ-MYH11] Table S10. Top 100 probe sets selected by SAM for MLL chimeric fusion genes Table S11. Top 100 probe sets selected by SAM for FAB-M7 Table S12. Top 100 probe sets selected by SAM for CBF leukemias (whole dataset) Section IV. MLL in combined ALL and AML dataset Table S13. Top 100 probe sets selected by SAM for MLL chimeric fusions irrespective of blast lineage (whole dataset) Table S14. Class discriminating genes for cases with an MLL chimeric fusion gene that show uniform high expression, irrespective of blast lineage Section V.
    [Show full text]
  • ( 12 ) United States Patent
    US009765324B2 (12 ) United States Patent ( 10 ) Patent No. : US 9 ,765 , 324 B2 Corgie et al. (45 ) Date of Patent: Sep. 19, 2017 (54 ) HIERARCHICAL MAGNETIC ( 2013 .01 ) ; C12N 11/ 14 ( 2013 .01 ); C12N 13/ 00 NANOPARTICLE ENZYME MESOPOROUS ( 2013 .01 ) ; C12P 7 /04 ( 2013 . 01 ) ; C12P 7 / 22 ASSEMBLIES EMBEDDED IN ( 2013 . 01 ) ; C12P 17 /02 ( 2013 .01 ) ; B01J MACROPOROUS SCAFFOLDS 35 / 1061 ( 2013 .01 ) ; B01J 35 / 1066 (2013 .01 ) ; BOIJ 2208 /00805 ( 2013 . 01 ) ; B01J 2219 /0854 (71 ) Applicant: CORNELL UNIVERSITY , Ithaca , NY ( 2013 .01 ) ; BOIJ 2219 /0862 ( 2013 .01 ) ; CO2F (US ) 2101/ 327 (2013 .01 ) ; CO2F 2209 / 006 (2013 . 01 ) ; CO2F 2303 /04 (2013 .01 ) ; (72 ) Inventors : Stephane C . Corgie , Ithaca , NY (US ) ; Xiaonan Duan , Ithaca, NY (US ) ; ( Continued ) Emmanuel Giannelis , Ithaca , NY (US ) ; (58 ) Field of Classification Search Daniel Aneshansley , Ithaca , NY (US ) ; None Larry P . Walker , Ithaca , NY (US ) See application file for complete search history . (73 ) Assignee : CORNELL UNIVERSITY , Ithaca , NY (56 ) References Cited (US ) U . S . PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer, the term of this 4 , 152, 210 A 5 / 1979 Robinson et al. patent is extended or adjusted under 35 6 , 440 , 711 B18 / 2002 Dave U . S . C . 154 ( b ) by 73 days. (Continued ) ( 21) Appl. No .: 14 /433 , 242 FOREIGN PATENT DOCUMENTS CN 1580233 A * 2 / 2005 ( 22 ) PCT Filed : Oct. 4 , 2013 CN 101109016 A 1 / 2008 ( 86 ) PCT No .: PCT/ US2013 / 063441 (Continued ) $ 371 ( c ) ( 1 ), OTHER PUBLICATIONS ( 2 ) Date : Apr. 2 , 2015 Corgie S . et al . Self Assembled Complexes of Horseradish (87 ) PCT Pub . No.
    [Show full text]
  • Uremic Toxicity of Advanced Glycation End Products in CKD
    BRIEF REVIEW www.jasn.org Uremic Toxicity of Advanced Glycation End Products in CKD † ‡ ‡ Andréa E.M. Stinghen,* Ziad A. Massy,* Helen Vlassara, § Gary E. Striker, § and | Agnès Boullier* *Institut National de la Santé et de la Recherche Médicale (INSERM) U-1088, Jules Verne University of Picardie, Amiens, France; †Division of Nephrology, Ambroise Paré University Medical Center, Assistance Publique-Hôpitaux de Paris (APHP), University of Paris Ouest, University Versailles-Saint Quentin, Boulogne Billancourt/Paris, France; ‡Division of Experimental Diabetes and Aging, Departments of Geriatrics and Palliative Care and Medicine and §Division of Experimental Diabetes and Aging, Department of Geriatrics and Aging and Division of Nephrology, Department of Medicine, Icahn School of Medicine, New York, New York; and |Biochemistry Laboratory, Amiens University Medical Center, Amiens, France ABSTRACT Advanced glycation end products (AGEs), a heterogeneous group of compounds include the 1,2-dicarbonyl compounds formed by nonenzymatic glycation reactions between reducing sugars and amino glyoxal and methylglyoxal (MG), a highly acids, lipids, or DNA, are formed not only in the presence of hyperglycemia, but also in reactive dicarbonyl compound.7 At least diseases associated with high levels of oxidative stress, such as CKD. In chronic renal 20 different types of AGE have been de- failure, higher circulating AGE levels result from increased formation and decreased scribed: N-carboxymethyllysine (CML), renal clearance. Interactions between AGEs and
    [Show full text]
  • Metabolic Network-Based Stratification of Hepatocellular Carcinoma Reveals Three Distinct Tumor Subtypes
    Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes Gholamreza Bidkhoria,b,1, Rui Benfeitasa,1, Martina Klevstigc,d, Cheng Zhanga, Jens Nielsene, Mathias Uhlena, Jan Borenc,d, and Adil Mardinoglua,b,e,2 aScience for Life Laboratory, KTH Royal Institute of Technology, SE-17121 Stockholm, Sweden; bCentre for Host-Microbiome Interactions, Dental Institute, King’s College London, SE1 9RT London, United Kingdom; cDepartment of Molecular and Clinical Medicine, University of Gothenburg, SE-41345 Gothenburg, Sweden; dThe Wallenberg Laboratory, Sahlgrenska University Hospital, SE-41345 Gothenburg, Sweden; and eDepartment of Biology and Biological Engineering, Chalmers University of Technology, SE-41296 Gothenburg, Sweden Edited by Sang Yup Lee, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea, and approved November 1, 2018 (received for review April 27, 2018) Hepatocellular carcinoma (HCC) is one of the most frequent forms of of markers associated with recurrence and poor prognosis (13–15). liver cancer, and effective treatment methods are limited due to Moreover, genome-scale metabolic models (GEMs), collections tumor heterogeneity. There is a great need for comprehensive of biochemical reactions, and associated enzymes and transporters approaches to stratify HCC patients, gain biological insights into have been successfully used to characterize the metabolism of subtypes, and ultimately identify effective therapeutic targets. We HCC, as well as identify drug targets for HCC patients (11, 16–18). stratified HCC patients and characterized each subtype using tran- For instance, HCC tumors have been stratified based on the uti- scriptomics data, genome-scale metabolic networks and network lization of acetate (11). Analysis of HCC metabolism has also led topology/controllability analysis.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses By
    Downloaded from http://www.jimmunol.org/ by guest on September 23, 2021 Inducing is online at: average * The Journal of Immunology , 11 of which you can access for free at: 2013; 191:2956-2966; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication August 2013; doi: 10.4049/jimmunol.1300376 http://www.jimmunol.org/content/191/6/2956 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol cites 49 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 This article http://www.jimmunol.org/content/191/6/2956.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 23, 2021. The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
    [Show full text]
  • Supplemental Figures 04 12 2017
    Jung et al. 1 SUPPLEMENTAL FIGURES 2 3 Supplemental Figure 1. Clinical relevance of natural product methyltransferases (NPMTs) in brain disorders. (A) 4 Table summarizing characteristics of 11 NPMTs using data derived from the TCGA GBM and Rembrandt datasets for 5 relative expression levels and survival. In addition, published studies of the 11 NPMTs are summarized. (B) The 1 Jung et al. 6 expression levels of 10 NPMTs in glioblastoma versus non‐tumor brain are displayed in a heatmap, ranked by 7 significance and expression levels. *, p<0.05; **, p<0.01; ***, p<0.001. 8 2 Jung et al. 9 10 Supplemental Figure 2. Anatomical distribution of methyltransferase and metabolic signatures within 11 glioblastomas. The Ivy GAP dataset was downloaded and interrogated by histological structure for NNMT, NAMPT, 12 DNMT mRNA expression and selected gene expression signatures. The results are displayed on a heatmap. The 13 sample size of each histological region as indicated on the figure. 14 3 Jung et al. 15 16 Supplemental Figure 3. Altered expression of nicotinamide and nicotinate metabolism‐related enzymes in 17 glioblastoma. (A) Heatmap (fold change of expression) of whole 25 enzymes in the KEGG nicotinate and 18 nicotinamide metabolism gene set were analyzed in indicated glioblastoma expression datasets with Oncomine. 4 Jung et al. 19 Color bar intensity indicates percentile of fold change in glioblastoma relative to normal brain. (B) Nicotinamide and 20 nicotinate and methionine salvage pathways are displayed with the relative expression levels in glioblastoma 21 specimens in the TCGA GBM dataset indicated. 22 5 Jung et al. 23 24 Supplementary Figure 4.
    [Show full text]
  • HANDBOOK of FLAVOPROTEINS Volume 1 Oxidases, Dehydrogenases and Related Systems
    Russ Hille, Susan Miller, Bruce Palfey (Eds.) HANDBOOK OF FLAVOPROTEINS Volume 1 Oxidases, Dehydrogenases and Related Systems With contrib. by Donald Becker, Claudia Binda, Eduardo Ceccarelli, Pimchai Chaiyen, Antonio J. Costa Filho, Bastian Daniel, Corinna Dully, Dale Edmondson, Paul Fitzpatrick, Giovanni Gadda, Sandro Ghisla, Niels Henrik Gregersen, Hisashi Hemmi, Rikke Katrine Jentoft Olsen, Jung-Ja Kim, Peter Macheroux, Andrea Mattevi, Milagros Medina, Maria Cristina Nonato, Steven Rokita, Marilyn Schuman Jorns, John J. Tanner, Colin Thorpe, Shiao-Chun Tu, Maria A. Vanoni, Silvia Wallner, Thanyaporn Wongnate f Comprehensive treatment of the flavoenzymes f From basic oxidation-reduction and electron transfer chemistry and en- zyme biology to modern biotechnological applications of flavoproteins f Extensive color figures The dynamic field of flavin and flavoprotein biochemistry has seen rapid advancement in recent years. This comprehensive two volume set provi- des an overview of all aspects of contemporary research in this important class of enzymes. Topics treated include flavoproteins involved in energy generation, signal transduction and electron transfer (including respiration); oxygen activation by flavoproteins; the biology and biochemistry of complex flavoproteins; flavin and flavoprotein photochemistry/photophysics as well as biotechnological applications of flavoproteins. Recent developments in this field include new structures (including those of large membrane-integral 372 pp., 150 fig. electron transfer complexes containing
    [Show full text]
  • Discovery of High Affinity Receptors for Dityrosine Through Inverse Virtual Screening and Docking and Molecular Dynamics
    Article Discovery of High Affinity Receptors for Dityrosine through Inverse Virtual Screening and Docking and Molecular Dynamics Fangfang Wang 1,*,†, Wei Yang 2,3,† and Xiaojun Hu 1,* 1 School of Life Science, Linyi University, Linyi 276000, China; [email protected] 2 Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia, [email protected] 3 Arieh Warshel Institute of Computational Biology, the Chinese University of Hong Kong, 2001 Longxiang Road, Longgang District, Shenzhen 518000, China * Corresponding author: [email protected] † These authors contributed equally to this work. Received: 09 December 2018; Accepted: 23 December 2018; Published: date Table S1. Docking affinity scores for cis-dityrosine binding to binding proteins. Target name PDB/UniProtKB Type Affinity (kcal/mol) Galectin-1 1A78/P56217 Lectin -6.2±0.0 Annexin III 1AXN/P12429 Calcium/phospholipid Binding Protein -7.5±0.0 Calmodulin 1CTR/P62158 Calcium Binding Protein -5.8±0.0 Seminal Plasma Protein Pdc-109 1H8P/P02784 Phosphorylcholine Binding Protein -6.6±0.0 Annexin V 1HAK/P08758 Calcium/phospholipid Binding -7.4±0.0 Alpha 1 antitrypsin 1HP7/P01009 Protein Binding -7.6±0.0 Histidine-Binding Protein 1HSL/P0AEU0 Binding Protein -6.3±0.0 Intestinal Fatty Acid Binding Protein 1ICN/P02693 Binding Protein(fatty Acid) -9.1±0.0* Migration Inhibitory Factor-Related Protein 14 1IRJ/P06702 Metal Binding Protein -7.0±0.0 Lysine-, Arginine-, Ornithine-Binding Protein 1LST/P02911 Amino Acid Binding Protein -6.5±0.0
    [Show full text]
  • Microbial Hydroxysteroid Dehydrogenases: from Alpha to Omega
    microorganisms Review Microbial Hydroxysteroid Dehydrogenases: From Alpha to Omega Heidi L. Doden 1,2 and Jason M. Ridlon 1,2,3,4,5,* 1 Microbiome Metabolic Engineering Theme, Carl R. Woese Institute for Genomic Biology, Urbana, IL 61801, USA; [email protected] 2 Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA 3 Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA 4 Cancer Center of Illinois, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA 5 Department of Microbiology and Immunology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA * Correspondence: [email protected] Abstract: Bile acids (BAs) and glucocorticoids are steroid hormones derived from cholesterol that are important signaling molecules in humans and other vertebrates. Hydroxysteroid dehydrogenases (HSDHs) are encoded both by the host and by their resident gut microbiota, and they reversibly convert steroid hydroxyl groups to keto groups. Pairs of HSDHs can reversibly epimerize steroids from α-hydroxy conformations to β-hydroxy, or β-hydroxy to !-hydroxy in the case of !-muricholic acid. These reactions often result in products with drastically different physicochemical properties than their precursors, which can result in steroids being activators or inhibitors of host receptors, can affect solubility in fecal water, and can modulate toxicity. Microbial HSDHs modulate sterols associated with diseases such as colorectal cancer, liver cancer, prostate cancer, and polycystic ovary syndrome. Although the role of microbial HSDHs is not yet fully elucidated, they may have therapeutic potential as steroid pool modulators or druggable targets in the future.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]